Adicet Bio (FRA:1IJA) Short Interest

View and export this data going back to 2020. Start your Free Trial

What is Adicet Bio Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of Adicet Bio's Short Interest

For the Biotechnology subindustry, Adicet Bio's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Adicet Bio's Short Interest Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Adicet Bio's Short Interest distribution charts can be found below:

* The bar in red indicates where Adicet Bio's Short Interest falls into.

Adicet Bio (FRA:1IJA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Adicet Bio Inc (FRA:1IJA) » Definitions » Short Interest

Comparable Companies

Traded in Other Exchanges

ACET:USA

Address

200 Clarendon Street, Floor 6, Boston, MA, USA, 02116

Website

https://www.adicetbio.com

Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. The company is advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and improve persistence for durable activity in patients. The company operates and manages its business as one reportable and operating segment, which is the business of research and development of allogeneic immunotherapies for cancer and other diseases.

Adicet Bio (FRA:1IJA) Headlines

No Headlines